Drugs / AG-86893
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03533244 | Oct 2018 → Sep 2019 | pterygium | Allgenesis Biotherapeutics Inc. | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2020-01-21 | Allgenesis Biotherapeutics Inc. | Results Allgenesis: Final Database Lock Reaffirms Excellent Safety, Tolerability, and Signs of Efficacy from POC Phase 2a Study of AG-86893 in Patients with Pterygium allgenesis.com ↗
Analysis from our final data base lock came in as expected and confirms our initial findings |
| 2019-10-18 | Allgenesis Biotherapeutics Inc. | Results Allgenesis sees Excellent Safety, Tolerability, and Signs of Efficacy from its Ongoing POC Phase 2a Study of AG-86893 in Patients with Pterygium allgenesis.com ↗
Allgenesis Biotherapeutics, a clinical stage biopharmaceutical company focused on research and development of novel medicines for the treatment of eye diseases, today announced that the early topline results showed promising safety, tolerability, and signs of efficacy from its ongoing SURPH Phase 2a Study of AG-86893 in patients with Pterygium. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-06-22 | Allgenesis Biotherapeutics Inc. | Allgenesis Receives Notice of Grant for AG-86893 in Korea and Japan for the Treatment of Pterygium allgenesis.com ↗ |
| 2020-01-21 | Allgenesis Biotherapeutics Inc. | Allgenesis: Final Database Lock Reaffirms Excellent Safety, Tolerability, and Signs of Efficacy from POC Phase 2a Study of AG-86893 in Patients with Pterygium allgenesis.com ↗ |
| 2019-10-18 | Allgenesis Biotherapeutics Inc. | Allgenesis sees Excellent Safety, Tolerability, and Signs of Efficacy from its Ongoing POC Phase 2a Study of AG-86893 in Patients with Pterygium allgenesis.com ↗ |
| 2019-09-25 | Allgenesis Biotherapeutics Inc. | Allgenesis Provides Timing Update of SURPH Phase 2a Clinical Trial for AG-86893 for the Treatment of Pterygium allgenesis.com ↗ |
| 2019-05-24 | Allgenesis Biotherapeutics Inc. | Phase 2a SURPH Trial for AG-86893 allgenesis.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AG-86893 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03533244 ↗ |
| Route | Topical | “Topical AG-86893” NCT03533244 ↗ |